Ginkgo plans to divest its biosecurity business to focus investments on autonomous labs, allowing for more targeted growth. The company has significantly reduced its cash burn by 55% in 2025 and secured a $47 million deal with Pacific Northwest National Labs, showcasing interest from federal entities in autonomous labs.
Cyborg Score Rationale
Despite a 26% drop in cell engineering revenue in Q4 2025, the company has achieved a 55% reduction in cash burn. The score is held down by weak financial performance (shrinking revenue, large net losses, and continued cash burn), offset by cost discipline and liquidity improvements.
Top Insights
The company is expanding rack capacity from 50 to 100 units at its Boston facility to enable data point services, cloud lab services, and multi-year solutions deals that provide recurring revenue
The data points offering is well-received as bioAI models gain traction, with growing demand for large data sets to train these models from large pharma and biotech ML teams
Ginkgo agreed to divest its biosecurity unit to Tower Biosecurity while retaining approximately 20% of the equity in the combined platform
2026 cash burn guidance is expected in the range of $125 to $150 million, demonstrating ongoing investment while maintaining improved financial discipline
Named Competitors
Synthetic Biology Services — Cell engineering and synthetic biology services
Lab Automation — Laboratory automation and instrumentation
AI-Driven Drug Discovery — Computational biology and drug discovery platform
Recent Developments
(February 2026) Announced divestiture of Biosecurity segment to Tower Biosecurity, retaining minority stake